From Glioblastoma Treatments
Jump to navigationJump to search
Property Information
Drug Name Keppra (Levetiracetam)
FDA Approval Yes (as an anti-seizure medication, 1999)
Used for Seizure prevention in brain tumor patients, potential sensitizer for glioblastoma cells to temozolomide chemotherapy
Clinical Trial Phase Retrospective studies and laboratory research
Clinical Trial Explanation Not specified
Common Side Effects Common side effects associated with Keppra include fatigue, dizziness, and mood changes, but it is generally well-tolerated in the context of brain tumor treatment.
OS without Median OS for glioblastoma patients not taking Keppra: 16.7 months
OS with Median OS for glioblastoma patients taking Keppra during chemotherapy: 25.7 months
PFS without Median PFS for patients not taking Keppra: 6.7 months
PFS with Median PFS for patients taking Keppra: 9.4 months
Usefulness Rating 4
Usefulness Explanation Not specified
Toxicity Level 2
Toxicity Explanation Keppra (Levetiracetam) is generally well-tolerated when used in the treatment of glioblastoma. Its side effects including fatigue, dizziness, and mood changes are fairly mild. However, like all medication, it does come with some level of toxicity which is why it's ranked at a 2 on a scale of 1 to 5. It's important to always discuss potential side effects with your healthcare provider to ensure this treatment is a good fit for you.

Notes: Keppra has become a prevalent choice for seizure prevention in brain tumor patients, with emerging evidence suggesting it can also enhance the efficacy of temozolomide chemotherapy by inhibiting MGMT enzyme activity. Significant increases in progression-free and overall survival were observed in patients receiving Keppra alongside chemotherapy in a retrospective study. Further research is needed to understand the full scope of benefits and whether they extend to patients with unmethylated MGMT status.

From Ben Williams Book: Not specified

Loading comments...